Provided by Tiger Trade Technology Pte. Ltd.

Celularity Inc.

1.24
+0.02001.64%
Volume:10.90K
Turnover:13.45K
Market Cap:35.76M
PE:-0.37
High:1.28
Open:1.20
Low:1.20
Close:1.22
52wk High:4.35
52wk Low:1.01
Shares:28.84M
Float Shares:16.12M
Volume Ratio:2.04
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3522
EPS(LYR):-2.6446
ROE:-6367.24%
ROA:-25.03%
PB:-1.78
PE(LYR):-0.47

Loading ...

Press Release: Celularity Announces Closing of Financing Transactions

Dow Jones
·
Dec 23, 2025

Celularity Inc. held annual stockholder meeting

Reuters
·
Dec 20, 2025

Celularity Secures Up to $12M in Funding

Dow Jones
·
Dec 19, 2025

Celularity Inc - to Receive up to $12 Mln in Financing

THOMSON REUTERS
·
Dec 19, 2025

Press Release: Celularity Reaches Binding Term Sheets on Financing Transactions to Support Its Strategic Vision

Dow Jones
·
Dec 19, 2025

There Is A Reason Celularity Inc.'s (NASDAQ:CELU) Price Is Undemanding

Simply Wall St.
·
Dec 16, 2025

Celularity Inc - FDA Requires Limiting Outcome-Based Claims for Interfyl - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

Celularity Inc - Receives FDA Warning Letter on Marketing Material - SEC Filing

THOMSON REUTERS
·
Dec 06, 2025

FDA Warns Celularity Over Marketing Claims for Interfyl

Reuters
·
Dec 06, 2025

Celularity Inc. Announces Date for Upcoming Annual Stockholders Meeting

Reuters
·
Nov 08, 2025

BRIEF-Celularity - Enters Securities Purchase Agreement For Private Placement

Reuters
·
Oct 28, 2025

Celularity Inc - Enters Securities Purchase Agreement for Private Placement - SEC Filing

THOMSON REUTERS
·
Oct 28, 2025

Celularity Inc. Sells Series A Preferred Stock and Warrants in $2 Million Private Placement

Reuters
·
Oct 28, 2025

Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (Pda-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

THOMSON REUTERS
·
Oct 14, 2025